claims

1. A compound of Formula (I):

$$F^1\text{–}L^1\text{–}T\text{–}L^2\text{–}F^2 \quad (I)$$

or a pharmaceutically acceptable salt thereof, wherein:

F^1 and F^2 are each independently selected from ring systems A, B, C and D:


(Ring System A)


(Ring System B)


(Ring System C)


(Ring System D);

each R is independently selected from the group consisting of H, -C_1-C_{20} alkyl, -C_2-C_8 alkenyl, -C_2-C_8 alkynyl, halo, hydroxyl, alkoxy, -NH_2, -NH(C_1-C_8 alkyl), -N(C_1-C_8 alkyl)$_2$, -NO_2, -C_6-C_{14} aryl and -C_6-C_{14} heteroaryl, and wherein said -C_6-C_{14} aryl and -C_6-C_{14} heteroaryl are optionally substituted with 1 to 5 substituents independently selected from: -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -halo, -C_1-C_{10} alkylthio, -trifluoromethyl, -NH_2, -NH(C_1-C_8

alkyl), -N(C_1-C_8 alkyl)$_2$, -C_1-C_{10} alkyl-N(C_1-C_8 alkyl)$_2$, -C_1-C_3 alkylthio, -NO_2 or -C_1-C_{10} heterocyclyl, for each ring system in which R appears;

each V^1 is independently a bond, O, N(R) or S, for each ring system in which V^1 appears;

each V^2 is independently O, N(R) or S, for each ring system in which V^2 appears;

W^1 and W^2 are each independently H, or -C_1-C_5 alkyl, for each ring system in which W^1 and W^2 appear;

each X is independently -OH, -O-acyl, azido, halo, cyanate, thiocyanate, isocyanate, thioisocyanate, or  , for each ring system in which X appears;

each Y is independently selected from the group consisting of H, -C_1-C_8 alkyl-R^A, -C(O)R^A, -C(S)R^A, -C(O)OR^A, -$S(O)_2$OR^A, -C(O)N(R^A)$_2$, -C(S)N(R^A)$_2$, glycosyl, -NO_2 and -PO(OR^A)$_2$, for each ring system in which Y appears, wherein each R^A is independently selected from the group consisting of H, -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl and -C_1-C_{20} alkylN(R)$_2$, wherein said -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl and -C_1-C_{20} alkylN(R)$_2$ are optionally substituted with 1 to 3 subsitutents independently selected from R;

each Z is independently selected from the group consisting of H, and -C_1-C_8 alkyl and wherein said C_1-C_8 alkyl, are each optionally substituted with 1 to 3 subsitutents independently selected from R, for each ring system in which Z appears;

L^1 and L^2 are each independently a direct bond

T is selected from:



wherein each R^E is independently selected from the group consisting of H, -C_1-C_8 alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, -aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl, -C(O)OC_1-C_8 alkyl, -C(O)N(C_1-C_8 alkyl)$_2$, and -C(O)-halo, and wherein each R^E is optionally substituted with 1 to 3 subsitutents independently selected from R, and

-C(A^1)X^1-T^2-X^1C(B^1)-, where T^2 is:



wherein each X^1 is independently a bond wherein A^1 and B^1 are each independently =O,

wherein R^1, R^2, R^3, and R^4 are each independently H, wherein g and j are each independently 0 or 1 and m is 1 , and wherein D is -C_3-C_8 carbocyclo, where said -C_3-C_8 carbocyclo is optionally substituted with -R^E , -C(O)R^E, -C(O)OR^E, -N(R^E)$_2$, -N(R)C(O)R^E or -N(R)C(O)OR^E, and D is additionally optionally substituted by 1 to 2 R,

2. A compound of Formula (IIA):

L–P (IIA)

or a pharmaceutically acceptable salt thereof, wherein:

P is:

$F^1-L^1-T-L^2-F^2$

wherein:

F^1 and F^2 are each independently selected from ring systems A, B, C and D:



(Ring System A)



(Ring System B)


(Ring System C)


(Ring System D);

each R is independently selected from the group consisting of H, -C_1-C_{20} alkyl, -C_2-C_8 alkenyl, -C_2-C_8 alkynyl, halo, hydroxyl, alkoxy, -NH_2, -NH(C_1-C_8 alkyl), -N(C_1-C_8 alkyl)$_2$, -NO_2, -C_6-C_{14} aryl and -C_6-C_{14} heteroaryl, and wherein said -C_6-C_{14} aryl and -C_6-C_{14} heteroaryl are optionally substituted with 1 to 5 substituents independently selected from -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -halo, -C_1-C_{10} alkylthio, -trifluoromethyl, -NH_2, -NH(C_1-C_8 alkyl), -N(C_1-C_8 alkyl)$_2$, -C_1-C_{10} alkyl-N(C_1-C_8 alkyl)$_2$, -C_1-C_3 alkylthio, -NO_2 or -C_1-C_{10} heterocyclyl, for each ring system in which R appears;

each V^1 is independently a bond, O, N(R) or S, for each ring system in which V^1 appears;

each V^2 is independently O, N(R) or S, for each ring system in which V^2 appears;

W^1 and W^2 are each independently H, or -C_1-C_5 alkyl, for each ring system in which W^1 and W^2 appear;

each X is independently selected from -OH, -O-acyl, azido, halo, cyanate, thiocyanate, isocyanate, thioisocyanate, or  for each ring system in which X appears;

each Y is independently selected from a bond, H, -C(O)R^A, -C(S)R^A, -C(O)OR^A, -S(O)$_2$OR^A, -C(O)N(R^A)$_2$, -C(S)N(R^A)$_2$, glycosyl, -NO_2 and -P(O)(OR^A)$_2$ for each ring system in which Y appears, wherein each R^A is independently selected from H, -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl, -C_1-C_{20} alkylN(R)$_2$, -C_1-C_{20} alkylene, -C_1-C_8 heteroalkylene, -C_6-C_{14} arylene, aralkylene, -C_1-C_{10} heterocyclo, -C_3-C_8 carbocyclo

and -C_1-C_{20} alkylN(R)-, and R^F where said R^A is optionally substituted with 1 to 3 subsituents independently selected from R, and wherein one Y is divalent and is bonded to L,

R^F is -$N(R^5)QN(R^5)C(O)$- and is bonded to L at the carbonyl adjacent $N(R^5)$, wherein R^5 and R^6 are each independently selected from the group consisting of H, -C_1-C_8 alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, -aralkyl, -C_1-C_{10} heterocyclyl and -C_3-C_8 carbocyclyl, or R^5 or R^6 joins with a substituted carbon on Q to form a -C_1-C_{10} heterocyclic or -C_5-C_{14} heteroaryl ring, or R^5 and R^6 join together to form a -C_1-C_{10} heterocyclic or -C_5-C_{14} heteroaryl ring system, and where Q is -C_1-C_8 alkylene-, -C_1-C_8 heteroalkylene-, -C_6-C_{14} arylene-, -aralkylene-, -C_1-C_{10} heterocyclo- or -C_3-C_8 carbocyclo-, wherein Q, R^5 and R^6 are each independently optionally substituted with 1 to 3 subsituents independently selected from R;

each Z is independently selected from the group consisting of H, and -C_1-C_8 alkyl and wherein said C_1-C_8 alkyl, are each optionally substituted with 1 to 3 subsitutents independently selected from R, for each ring system in which Z appears;

L^1 and L^2 are each independently a direct bond

T is selected from:

wherein each R^E is independently selected from the group consisting of H, -C_1-C_8 alkyl, -C_1-C_8 heteroalkyl, -aryl, -aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl, -$C(O)OC_1$-C_8 alkyl, -$C(O)N(C_1$-C_8 alkyl$)_2$, and -C(O)-halo, and wherein each R^E is optionally substituted with 1 to 3 subsitutents independently selected from R,

-$C(A^1)X^1$-T^2-$X^1C(B^1)$-, where T^2 is:



wherein each X^1 is independently a bond wherein A^1 and B^1 are each independently =O wherein R^1, R^2, R^3, and R^4 are each independently H wherein g and j are each

independently 0 or 1 and m is 1 , and wherein D is $-C_3-C_8$ carbocyclo, where said $-C_3-C_8$ carbocyclo is optionally substituted with $-R^E$, $-C(O)R^E$, $-C(O)OR^E$, $-N(R^E)_2$, $-N(R)C(O)R^E$ or $-N(R)C(O)OR^E$, and D is additionally optionally substituted by 1 to 2 R;

L is L^A-L^B-$(L^C)_{1-3}$, wherein L^A is selected from the group consisting of -halo, $-N(R)_2$, $-CON(R)_2$, -S-aryl optionally substituted with $-NO_2$ or $-CON(R)_2$, -S-heteroaryl optionally substituted with $-NO_2$, alkyl-SO_2-heteroaryl, arylSO_2-heteroaryl-,


,

,

, and

,

L^B is L^{B1}-L^{B2}-L^{B3} wherein L^{B1} is absent or is one or more components selected from the group consisting of -C(O)- , -C(S)- , -C(O)NR-, $-C(O)C_1-C_6$alkyl-, $-C(O)NRC_1-C_6$alkyl-, $-C_1-C_6$alkyl$(OCH_2CH_2)_{1-6}$-, $-C(O)C_1-C_6$alkylNRC(O)-, $-C(O)C_1-C_6$alkyl$(OCH_2CH_2)_{1-6}$-, $-C_1-C_6$alkyl$(OCH_2CH_2)_{1-6}$-C(O)-, $-C_1-C_6$alkyl-S-S-C_1-C_6alkylNRC(O)CH_2-, $-C_1-C_6$alkyl$(OCH_2CH_2)_{1-6}$NRC(O)CH_2-, $-C(O)C_1-C_6$alkyl-NRC(O)C_{1-6}alkyl-, -N=CR-phenyl-O-C_1-C_6alkyl-, -N=CR-phenyl-O-C_1-C_6alkyl-C(O)-, $-C(O)-C_1-C_6$alkyl$(OCH_2CH_2)_{1-6}$NRC(O)-, $-C(O)C_1-C_6$alkyl-phenyl(NR-C(O)C_1-C_6alkyl$)_{1-4}$-, $-C(O)C_1-C_6$alkyl$(OCH_2CH_2)_{1-8}$-NRC(O)C_1-C_6alkyl-, $-C_1-C_6$alkyl-, -S-, -C(O)-CH(NR-C(O)C_1-C_6alkyl)-C_1-C_6alkyl- and $(-CH_2-CH_2-O-)_{1-20}$,

wherein L^{B2} is AA_{0-12}, wherein AA is a natural amino acid, or a non-natural amino acid,

L^{B3} is

,

or absent;

L^C is absent or independently selected from the group consisting of $-C_1-C_6$alkylene-, $-NRC_3-C_8$-heterocyclylNR-, $-NRC_3-C_8$-carbocyclylNR-, $-NRC_1-C_6$alkylNR-, $-NRC_1-C_6$alkylene-, -S-, -NR-, -NRNR-, $-O(CR_2)_{1-4}S-S(CR_2)_{1-4}N(R)$-, $-NRC_1-C_8$-alkylenephen

yleneNR-, -NRC$_1$-C$_6$alkylenephenyleneSO$_2$NR-, -OC$_1$-C$_6$alkylS-SC$_1$-C$_6$alkylC(COOR)NR-, -NRC(COOR)C$_1$-C$_6$alkylS-SC$_1$-C$_6$alkylO-,



and



wherein

X^A is CR or N ,

X^B is CH, CR(C(R)$_2$)$_{1-3}$NR, CR(C(R)$_2$)$_{1-3}$O, CR(C(R)$_2$)$_{1-3}$C(O)NR, CR-(C(R)$_2$)$_{1-3}$C(O)NRNR, CR(C(R)$_2$)$_{1-3}$SO$_2$NR, CR(C(R)$_2$)$_{1-3}$NRNR, CR(C(R)$_2$)$_{1-3}$NRC(O) or N,

each X^C is R,

each X^D is -(CH$_2$)$_{1-5}$-, or is absent;

X^E is O, S, C(R)$_2$, C(R)(C(R)$_2$)$_{1-3}$-NR$_2$ or NR and

each X^F is (C(R)$_2$)$_{1-3}$-NR or C(R)$_2$-(C(R)$_2$)$_{1-3}$-O.

3. A compound of Formula (IIIA):

$$AB-(L-P)_{1-20} \quad (IIIA)$$

or a pharmaceutically acceptable salt thereof, wherein:

AB is an antibody;

P is:

$F^1-L^1-T-L^2-F^2$

wherein:

F^1 and F^2 are each independently selected from ring systems A, B, C and D:


(Ring System A)


(Ring System B)


(Ring System C)


(Ring System D);

each R is independently selected from the group consisting of H, -C_1-C_{20} alkyl, -C_2-C_8 alkenyl, -C_2-C_8 alkynyl, halo, hydroxyl, alkoxy, -NH_2, -NH(C_1-C_8 alkyl), -N(C_1-C_8 alkyl)$_2$, -NO_2, -C_6-C_{14} aryl and -C_6-C_{14} heteroaryl, and wherein said -C_6-C_{14} aryl and -C_6-C_{14} heteroaryl are optionally substituted with 1 to 5 substituents independently selected from -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -halo, -C_1-C_{10} alkylthio, -trifluoromethyl, -NH_2, -NH(C_1-C_8 alkyl), -N(C_1-C_8 alkyl)$_2$, -C_1-C_{10} alkyl-N(C_1-C_8 alkyl)$_2$, -C_1-C_3 alkylthio, -NO_2 or -C_1-C_{10} heterocyclyl, for each ring system in which R appears;

each V^1 is independently a bond, O, N(R) or S, for each ring system in which V^1 appears;

each V^2 is independently O, N(R) or S, for each ring system in which V^2 appears;

W^1 and W^2 are each independently H, or -C_1-C_8alkyl for each ring system in which W^1 and W^2 appear;

each X is independently selected from -OH, -O-acyl, azido, halo, cyanate, thiocyanate, isocyanate, thioisocyanate, or  , for each ring system in which X appears;

each Y is independently selected from a bond, H, -C(O)R^A, -C(S)R^A, -C(O)OR^A, -$S(O)_2$OR^A, -C(O)N(R^A)$_2$, -C(S)N(R^A)$_2$, glycosyl, -NO_2 and -P(O)(OR^A)$_2$ for each ring system in which Y appears, wherein each R^A is independently selected from H, -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl, -C_1-C_{20} alkylN(R)$_2$, -C_1-C_{20} alkylene, -C_1-C_8 heteroalkylene, -C_6-C_{14} arylene, aralkylene, -C_1-C_{10} heterocyclo, -C_3-C_8 carbocyclo and -C_1-C_{20} alkylN(R)-, and R^F where said R^A is optionally substituted with 1 to 3 subsituents independently selected from R, and wherein one Y is divalent and is bonded to L,

R^F is -N(R^6)QN(R^5)C(O)- and is bonded to L at the carbonyl adjacent N(R^5), wherein R^5 and R^6 are each independently selected from the group consisting of H, -C_1-C_8 alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, -aralkyl, -C_1-C_{10} heterocyclyl and -C_3-C_8 carbocyclyl, or R^5 or R^5 joins with a substituted carbon on Q to form a -C_1-C_{10} heterocyclic or -C_6-C_{14} heteroaryl ring, or R^5 and R^6 join together to form a -C_1-C_{10} heterocyclic or -C_6-C_{14} heteroaryl ring system, and where Q is -C_1-C_8 alkylene-, -C_1-C_8 heteroalkylene-, -C_6-C_{14} arylene-, -aralkylene-, -C_1-C_{10} heterocyclo- or -C_3-C_8 carbocyclo-, wherein Q, R^5 and R^6 are each independently optionally substituted with 1 to 3 subsituents independently selected from R;

each Z is independently selected from the group consisting of H, and -C_1-C_8 alkyl and wherein said C_1-C_8 alkyl, is each optionally substituted with 1 to 3 subsitutents independently selected from R, for each ring system in which Z appears;

L^1 and L^2 are each independently a direct bond

wherein each R^E is independently selected from the group consisting of H, -C_1-C_8 alkyl, -C_1-C_8 heteroalkyl, -aryl, -aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl, -C(O)OC_1-C_8 alkyl, -C(O)N(C_1-C_8 alkyl)$_2$, and -C(O)-halo, and wherein each R^E is optionally substituted with 1 to 3 subsitutents independently selected from R,

-C(A^1)X^1-T^2-X^{1}C(B^1)-, where T^2 is:



wherein each X^1 is independently a bond, wherein A^1 and B^1 are each independently =O wherein R^1 , R^2, R^3, and R^4 are each independently H wherein g and j are each independently 0 or 1 and m is 1, and wherein D is -C$_3$-C$_8$ carbocyclo, where said –C$_3$-C$_8$ carbocyclo is optionally substituted with –R^E , -C(O)R^E, -C(O)OR^E, -N(R^E)$_2$, -N(R)C(O)R^E or -N(R)C(O)OR^E, and D is additionally optionally substituted by 1 to 2 R;

L is L^A-L^B-(L^C)$_{1-3}$;

L^A is selected from: a bond to AB, -NR-(bond to AB), alkyl-SO$_2$-heteroaryl, arylSO$_2$-heteroaryl-,



,


and


;

L^B is L^{B1}-L^{B2}-L^{B3}

wherein L^{B1} is absent or is one or more components selected from the group consisting of -C(O)- , -C(S)- , -C(O)NR-, -C(O)C$_1$-C$_6$alkyl-, -C(O)NRC$_1$-C$_6$alkyl-, -C$_1$-C$_6$alkyl(OCH$_2$CH$_2$)$_{1-6}$-, -C(O)C$_1$-C$_6$alkylNRC(O)-, -C(O)C$_1$-C$_6$alkyl(OCH$_2$CH$_2$)$_{1-6}$-, -C$_1$-C$_6$alkyl(OCH$_2$CH$_2$)$_{1-6}$-C(O)-, -C$_1$-C$_6$alkyl-S-S-C$_1$-C$_6$alkylNRC(O)CH$_2$-, -C$_1$-C$_6$alkyl(OCH$_2$CH$_2$)$_{1-6}$NRC(O)CH$_2$-, -C(O)C$_1$-C$_6$alkyl-NRC(O)C$_{1-6}$alkyl-, -N=CR-phenyl-O-C$_1$-C$_6$alkyl-, -N=CR-phenyl-O-C$_1$-C$_6$alkyl-C(O)-, -C(O)-C$_1$-C$_6$alkyl(OCH$_2$CH$_2$)$_{1-6}$NRC(O)-, -C(O)C$_1$-C$_6$alkyl-phenyl(NR-C(O)C$_1$-C$_6$alkyl)$_{1-4}$-, -C(O)C$_1$-C$_6$alkyl(OCH$_2$CH$_2$)$_{1-6}$-NRC(O)C$_1$-C$_6$alkyl-, -C$_1$-C$_6$alkyl-, -S-, -C(O)-CH(NR-C(O)C$_1$-C$_6$alkyl)-C$_1$-C$_6$alkyl- and (-CH$_2$-CH$_2$-O-)$_{1-20}$;

L^{B2} is AA$_{0-12}$, wherein AA is a natural amino acid, or a non-natural amino acid,

L^{B3} is  ,  or absent,

L^C is absent or is independently selected from the group consisting of $-C_1$-C_6alkylene-, $-NRC_3$-C_8-heterocyclylNR-, $-NRC_3$-C_8-carbocyclylNR-, $-NRC_1$-C_6alkylNR-, $-NRC_1$-C_6alkylene-, -S-, -NR-, -NRNR-, $-O(CR_2)_{1-4}S$-$S(CR_2)_{1-4}N(R)$-, $-NRC_1$-C_6-alkylenephenyleneNR-, $-NRC_1$-C_6alkylenephenyleneSO$_2$NR-, $-OC_1$-C_6alkylS-SC_1-C_6alkylC(COOR)NR-, -NRC(COOR)C_1-C_6alkylS-SC_1-C_6alkylO-,

 ,  

and  ,

wherein

X^A is CR or N,

X^B is CH, $CR(C(R)_2)_{1-3}NR$, $CR(C(R)_2)_{1-3}O$, $CR(C(R)_2)_{1-3}C(O)NR$, CR-$(C(R)_2)_{1-3}C(O)NRNR$, $CR(C(R)_2)_{1-3}SO_2NR$, $CR(C(R)_2)_{1-3}NRNR$, $CR(C(R)_2)_{1-3}NRC(O)$ or N,

each X^C is R;

each X^D is $-(CH_2)_{1-5}-$, or is absent;

X^E is O, S, $C(R)_2$, $C(R)(C(R)_2)_{1-3}$-NR_2 or NR, and

each X^F is $(C(R)_2)_{1-3}$-NR or $C(R)_2$-$(C(R)_2)_{1-3}$-O .

4. A compound of Formula (IIB):

$$F^1\text{-}L^1\text{-}T\text{-}L^2\text{-}F^2$$
$$\quad\quad L \quad\quad \text{(IIB)}$$

or a pharmaceutically acceptable salt thereof, wherein:

F^1 and F^2 are each independently selected from ring systems A, B, C and D:


(Ring System A)


(Ring System B)


(Ring System C)


(Ring System D);

each R is independently selected from the group consisting of H, -C_1-C_{20} alkyl, -C_2-C_8 alkenyl, -C_2-C_8 alkynyl, halo, hydroxyl, alkoxy, -NH_2, -NH(C_1-C_8 alkyl), -N(C_1-C_8 alkyl)$_2$, -NO_2, -C_6-C_{14} aryl and -C_6-C_{14} heteroaryl, and wherein said -C_6-C_{14} aryl and -C_6-C_{14} heteroaryl are optionally substituted with 1 to 5 substituents independently selected from -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -halo, -C_1-C_{10} alkylthio, -trifluoromethyl, -NH_2, -NH(C_1-C_8 alkyl), -N(C_1-C_8 alkyl)$_2$, -C_1-C_{10} alkyl-N(C_1-C_8 alkyl)$_2$, -C_1-C_3 alkylthio, -NO_2 or -C_1-C_{10} heterocyclyl, for each ring system in which R appears;

each V^1 is independently a bond, O, N(R) or S, for each ring system in which V^1 appears;

each V^2 is independently O, N(R) or S, for each ring system in which V^2 appears;

W^1 and W^2 are each independently H, or -C_1-C_8 alkyl, for each ring system in which W^1 and W^2 appear;

each X is independently -OH, -O-acyl, azido, halo, cyanate, thiocyanate, isocyanate, thioisocyanate, or  , for each ring system in which X appears;

each Y is independently selected from the group consisting of H, -C_1-C_8 alkyl-R^A, -C(O)R^A, -C(S)R^A, -C(O)OR^A, -$S(O)_2OR^A$, -C(O)N(R^A)$_2$, -C(S)N(R^A)$_2$, glycosyl, -NO_2 and -$PO(OR^A)_2$, for each ring system in which Y appears, wherein each R^A is independently selected from the group consisting of H, -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl and -C_1-C_{20} alkylN(R)$_2$, wherein said -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl and -C_1-C_{20} alkylN(R)$_2$ are optionally substituted with 1 to 3 subsitutents independently selected from R;

each Z is independently selected from the group consisting of H, and -C_1-C_8 alkyl and wherein said C_1-C_8 alkyl is each optionally substituted with 1 to 3 subsitutents independently selected from R, for each ring system in which Z appears;

L^1 and L^2 are each independently a direct bond

T is selected from:

-C(A^1)X^1-T^2-X^1C(B^1)-, where T^2 is:



wherein each X^1 is independently a bond -wherein A^1 and B^1 are each independently =O, wherein R^1 , R^2, R^3, and R^4 are each independently H, wherein g and j are each independently 0 or 1 and m is 1, and wherein D is -C_3-C_8 carbocyclo, where said -C_3-C_8 carbocyclo is substituted with one member of the group selected from N(R^E)C(O)- where the

carbonyl is bonded to L, and -C(O)- where the carbonyl is bonded to L, and additionally optionally substituted by 1 to 2 R;

where each R^E is independently selected from the group consisting of H, -C_1-C_8 alkyl, -C_1-C_8 heteroalkyl, -aryl, -aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl, -C(O)OC_1-C_8 alkyl, -C(O)N(C_1-C_8 alkyl)$_2$, and -C(O)-halo, and wherein each R^E is optionally substituted with 1 to 3 subsitutents independently selected from R;

L is L^A-L^B-$(L^C)_{1-3}$;

L^A is selected from -halo, -N(R)$_2$, -CON(R)$_2$, -S-aryl optionally substituted with -NO_2 or -CONR$_2$, -S-heteroaryl optionally substituted with -NO_2, alkyl-SO_2-heteroaryl, arylSO_2-heteroaryl-;



L^B is L^{B1}-L^{B2}-L^{B3}

wherein L^{B1} is absent or is one or more components selected from the group consisting of -C(O)-, -C(S)-, -C(O)NR-, -C(O)C_1-C_6alkyl-, -C(O)NRC_1-C_6alkyl-, -C_1-C_8alkyl$(OCH_2CH_2)_{1-6}$-, -C(O)C_1-C_6alkylNRC(O)-, -C(O)C_1-C_6alkyl$(OCH_2CH_2)_{1-6}$-, -C_1-C_8alkyl$(OCH_2CH_2)_{1-6}$-C(O)-, -C_1-C_6alkyl-S-S-C_1-C_6alkylNRC(O)CH_2-, -C_1-C_6alkyl$(OCH_2CH_2)_{1-6}$NRC(O)CH_2-, -C(O)C_1-C_6alkyl-NRC(O)C_{1-6}alkyl-, -N=CR-phenyl-O-C_1-C_6alkyl-, -N=CR-phenyl-O-C_1-C_6alkyl-C(O)-, -C(O)-C_1-C_6alkyl$(OCH_2CH_2)_{1-6}$NRC(O)-, -C(O)C_1-C_6alkyl-phenyl$(NR\text{-}C(O)C_1\text{-}C_8alkyl)_{1-4}$-, -C(O)$C_1$-$C_6$alkyl$(OCH_2CH_2)_{1-6}$-NRC(O)$C_1$-$C_6$alkyl-, -$C_1$-$C_6$alkyl-, -S-, -C(O)-CH(NR-C(O)C_1-C_6alkyl)-C_1-C_6alkyl- and $(-CH_2\text{-}CH_2\text{-}O-)_{1-20}$;

L^{B2} is AA_{0-12}, wherein AA is a natural amino acid, or a non-natural amino acid,

L^{B3} is  or is absent;

L^C is absent or is independently selected from the group consisting of -C_1-C_8alkylene-, -NRC_3-C_8-heterocyclylNR-, -NRC_3-C_8-carbocyclylNR-, -NRC_1-C_6alkylNR-, -NRC_1-C_6alkylene-, -S-, -NR-, -NRNR- , -O$(CR_2)_{1-4}$S-S$(CR_2)_{1-4}$N(R)-, -NRC_1-C_8-alkylenephenyleneNR-, -NRC_1-C_6alkylenephenyleneSO_2NR-, -OC_1-C_5alkylS-SC_1-C_5alkylC(COOR)NR-, -NRC(COOR)C_1-C_5alkylS-SC_1-C_5alkylO-,

 ,  , 

and  ,

wherein

X^A is CR or N,

X^B is CH, CR$(C(R)_2)_{1-3}$NR, CR$(C(R)_2)_{1-3}$O, CR$(C(R)_2)_{1-3}$C(O)NR, CR-$(C(R)_2)_{1-3}$C(O)NRNR, CR$(C(R)_2)_{1-3}S O_2$NR, CR$(C(R)_2)_{1-3}$NRNR, CR$(C(R)_2)_{1-3}$NRC(O) or N;

each X^C is R;

each X^D is -$(CH_2)_{1-5}$-, or is absent;

X^E is O, S, $C(R)_2$, $C(R)(C(R)_2)_{1-3}$-NR_2 or NR, and

each X^F is $(C(R)_2)_{1-3}$-NR or $C(R)_2$-$(C(R)_2)_{1-3}$-O.

5. A compound of Formula (IIIB):



(IIIB)

or a pharmaceutically acceptable salt thereof, wherein:

AB is an antibody;

F^1 and F^2 are each independently selected from ring systems A, B, C and D:



(Ring System A)



(Ring System B)



(Ring System C)



(Ring System D);

each R is independently selected from the group consisting of H, -C_1-C_{20} alkyl, -C_2-C_8 alkenyl, -C_2-C_8 alkynyl, halo, hydroxyl, alkoxy, -NH_2, -NH(C_1-C_8 alkyl), -N(C_1-C_8 alkyl)$_2$, -NO_2, -C_6-C_{14} aryl and -C_5-C_{14} heteroaryl, and wherein said -C_6-C_{14} aryl and -C_5-C_{14} heteroaryl are optionally substituted with 1 to 5 substituents independently selected from -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -halo, -C_1-C_{10} alkylthio, -trifluoromethyl, -NH_2, -NH(C_1-C_8 alkyl), -N(C_1-C_8 alkyl)$_2$, -C_1-C_{10} alkyl-N(C_1-C_8 alkyl)$_2$, -C_1-C_3 alkylthio, -NO_2 or -C_1-C_{10} heterocyclyl, for each ring system in which R appears;

each V^1 is independently a bond, O, N(R) or S, for each ring system in which V^1 appears;

each V^2 is independently O, N(R) or S, for each ring system in which V^2 appears;

W^1 and W^2 are each independently H, or -C_1-C_5 alkyl for each ring system in which W^1 and W^2 appear;

each X is independently -OH, -O-acyl, azido, halo, cyanate, thiocyanate, isocyanate, thioisocyanate, or  , for each ring system in which X appears;

each Y is independently selected from the group consisting of H, -C_1-C_6 alkyl-R^A, -C(O)R^A, -C(S)R^A, -C(O)OR^A, -S(O)$_2$OR^A, -C(O)N(R^A)$_2$, -C(S)N(R^A)$_2$, glycosyl, -NO_2 and -PO(OR^A)$_2$, for each ring system in which Y appears, wherein each R^A is independently selected from the group consisting of H, -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl and -C_1-C_{20} alkylN(R)$_2$, wherein said -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl and -C_1-C_{20} alkylN(R)$_2$ are optionally substituted with 1 to 3 subsitutents independently selected from R;

each Z is independently selected from the group consisting of H, and -C_1-C_6 alkyl and wherein said C_1-C_6 alkyl is each optionally substituted with 1 to 3 subsitutents independently selected from R, for each ring system in which Z appears;

L^1 and L^2 are each independently a direct bond

T is selected from:

-C(A^1)X^1-T^2-X^1C(B^1)-, where T^2 is:



wherein each X^1 is independently a bond wherein A^1 and B^1 are each independently =O , wherein R^1 , R^2, R^3, and R^4 are each independently H , wherein g and j are each independently 0 or 1 and m is 1, and wherein D is -C_3-C_8 carbocyclo, where said -C_3-C_8 carbocyclo is substituted with one member of the group selected from $N(R^E)C(O)$- where the carbonyl is bonded to L, and -C(O)- where the carbonyl is bonded to L, and additionally optionally substituted by 1 to 2 R;

where each R^E is independently selected from the group consisting of H, -C_1-C_8 alkyl, -C_1-C_8 heteroalkyl, -aryl, -aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl, -C(O)OC_1-C_8 alkyl, -C(O)N(C_1-C_8 alkyl)$_2$, and -C(O)-halo, and wherein each R^E is optionally substituted with 1 to 3 substitutents independently selected from R;

L is L^A-L^B-$(L^C)_{1-3}$;

L^A is selected from: a bond to AB, -NR-(bond to AB), alkyl-SO_2-heteroaryl, arylSO_2-heteroaryl-,



,


and


; L^B is L^{B1}-L^{B2}-L^{B3}

wherein L^{B1} is absent or is one or more components selected from the group consisting of -C(O)- , -C(S)- , -C(O)NR-, -C(O)C_1-C_6alkyl-, -C(O)NRC_1-C_6alkyl-, -C_1-C_6alkyl$(OCH_2CH_2)_{1-5}$-, -C(O)C_1-C_6alkylNRC(O)-, -C(O)C_1-C_6alkyl$(OCH_2CH_2)_{1-5}$-, -C_1-C_6alkyl$(OCH_2CH_2)_{1-5}$-C(O)-, -C_1-C_6alkyl-S-S-C_1-C_6alkylNRC(O)CH_2-, -C_1-C_6alkyl$(OCH_2CH_2)_{1-5}$NRC(O)CH_2-, -C(O)C_1-C_6alkyl-NRC(O)C_1-C_6alkyl-, -N=CR-phenyl-O-C_1-C_6alkyl-, -N=CR-phenyl-O-C_1-C_6alkyl-C(O)-, -C(O)-C_1-C_6alkyl$(OCH_2CH_2)_{1-6}$NRC(O)-, -C(O)C_1-C_6alkyl-phenyl(NR-C(O)C_1-C_6alkyl)$_{1-4}$-, -C(O)C_1-C_6alkyl$(OCH_2CH_2)_{1-5}$-NRC(O)C_1-C_6alkyl-, -C_1-C_6alkyl-, -S-, -C(O)-CH(NR-C(O)C_1-C_6alkyl)-C_1-C_6alkyl- and $(-CH_2-CH_2-O-)_{1-20}$;

L^{B2} is AA_{0-12}, wherein AA is a natural amino acid, or a non-natural amino acid,

L^{B3} is  ,  or absent;

L^C is absent or is independently selected from the group consisting of -C_1-C_8alkylene-, -NRC_3-C_8-heterocyclylNR-, -NRC_3-C_8-carbocyclylNR-, -NRC_1-C_8alkylNR-, -NRC_1-C_8alkylene-, -S-, -NR-, -NRNR- , -O$(CR_2)_{1-4}$S-S$(CR_2)_{1-4}$N(R)-, -NRC_1-C_8-alkylenephenyleneNR-, -NRC_1-C_8alkylenephenyleneSO$_2$NR-, -OC_1-C_8alkylS-SC_1-C_8alkylC(COOR)NR-, -NRC(COOR)C_1-C_8alkylS-SC_1-C_8alkylO-,

 ,  

and  ,

wherein

X^A is CR or N,

X^B is CH, CR$(C(R)_2)_{1-3}$NR, CR$(C(R)_2)_{1-3}$O, CR$(C(R)_2)_{1-3}$C(O)NR, CR-$(C(R)_2)_{1-3}$C(O)NRNR, CR$(C(R)_2)_{1-3}$SO$_2$NR, CR$(C(R)_2)_{1-3}$NRNR, CR$(C(R)_2)_{1-3}$NRC(O) or N;

each X^C is R;

each X^D is -$(CH_2)_{1-5}$-, or is absent;

X^E is O, S, C(R)$_2$, C(R)$(C(R)_2)_{1-3}$-NR$_2$ or NR, and

each X^F is $(C(R)_2)_{1-3}$-NR or C(R)$_2$-$(C(R)_2)_{1-3}$-O.

6. The compound of claim 1, or a pharmaceutically acceptable salt, wherein:

each R is independently selected from the group consisting of H, -C_1-C_{20} alkyl and -NH_2;

each V^1 is independently O or N(R) for each ring system in which V^1 appears;

each V^2 is independently O or N(R) for each ring system in which V^2 appears;

W^1 and W^2 are each independently H, or -C_1-C_6 alkyl for each ring system in which W^1 and W^2 appear;

each X is independently halo, for each ring system in which X appears;

each Y is independently selected from the group consisting of H, -$C(O)R^A$, -$C(O)N(R^A)_2$, glycosyl, -NO_2 and -$PO(OR^A)_2$, for each ring system in which Y appears, wherein each R^A is independently selected from the group consisting of H, -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_3-C_8 carbocyclyl and -C_1-C_{20} alkyl$N(R)_2$, wherein said -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_3-C_8 carbocyclyl and -C_1-C_{20} alkyl$N(R)_2$ are optionally substituted with 1 to 3 substitutents independently selected from R;

L^1 and L^2 are each independently a direct bond ; and

T is selected from:

-$C(A^1)X^1$-T^2-$X^1C(B^1)$-, where T^2 is:



wherein each X^1 is a bond, wherein A^1 and B^1 are each independently =O, wherein R^1, R^2, R^3, and R^4 are each independently H , and wherein D is -C_3-C_8 carbocyclo, where said -C_3-C_8 carbocyclo is optionally substituted with -NH_2, -N(R)C(O)H or -N(R)C(O)OH.

7. The compound of any of claims 2-3, or a pharmaceutically acceptable salt, wherein:

each R is independently selected from the group consisting of H, -C_1-C_{20} alkyl and -NH_2;

each V^1 is independently O or N(R) for each ring system in which V^1 appears;

each V^2 is independently O or N(R) for each ring system in which V^2 appears;

W^1 and W^2 are each independently H or -C_1-C_5 alkyl for each ring system in which W^1 and W^2 appear;

each X is independently halo, for each ring system in which X appears;

each Y is independently selected from a bond, H, $-C(O)R^A$, $-C(S)R^A$, $-C(O)OR^A$, $-S(O)_2OR^A$, $-C(O)N(R^A)_2$, $-C(S)N(R^A)_2$, glycosyl, $-NO_2$ and $-P(O)(OR^A)_2$ for each ring system in which Y appears, wherein each R^A is independently selected from H, -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_6-C_{14} aryl, aralkyl, -C_1-C_{10} heterocyclyl, -C_3-C_8 carbocyclyl, -C_1-C_{20} alkyl$N(R)_2$, -C_1-C_{20} alkylene, -C_1-C_8 heteroalkylene, -C_6-C_{14} arylene, aralkylene, -C_1-C_{10} heterocyclo, -C_3-C_8 carbocyclo and -C_1-C_{20} alkylN(R)-, and R^F where said R^A is optionally substituted with 1 to 3 subsituents independently selected from R, and wherein one Y is divalent and is bonded to L,

R^F is $-N(R^5)QN(R^5)C(O)-$ and is bonded to L at the carbonyl adjacent $N(R^5)$, wherein R^5 and R^6 are each independently selected from the group consisting of H, -C_1-C_8 alkyl, and -C_1-C_8 heteroalkyl, or R^5 or R^6 joins with a substituted carbon on Q to form a -C_1-C_{10} heterocyclic or -C_6-C_{14} heteroaryl ring, or R^5 and R^6 join together to form a -C_1-C_{10} heterocyclic or -C_5-C_{14} heteroaryl ring system, and where Q is -C_1-C_8 alkylene-, -C_6-C_{14} arylene-, or -C_3-C_8 carbocyclo-, wherein Q, R^5 and R^6 are each independently optionally substituted with 1 to 3 subsituents independently selected from R;

L^1 and L^2 are each independently selected from a direct bond; and

T is selected from:

$-C(A^1)X^1-T^2-X^1C(B^1)-$, where T^2 is:



wherein each X^1 is a bond, wherein A^1 and B^1 are each independently =O, wherein R^1, R^2, R^3, and R^4 are each independently H wherein g and j are each independently 0 or 1 and m is

1, and wherein D is -C_3-C_8 carbocyclo, where said -C_3-C_8 carbocyclo is optionally substituted with -NH_2, -N(R)C(O)H or -N(R)C(O)OH.

8. The compound of any of claims 4-5, or a pharmaceutically acceptable salt, wherein:

each R is independently selected from the group consisting of H, -C_1-C_{20} alkyl and -NH_2;

each V^1 is independently O or N(R) for each ring system in which V^1 appears;

each V^2 is independently O or N(R) for each ring system in which V^2 appears;

W^1 and W^2 are each independently H, or -C_1-C_8 alkyl for each ring system in which W^1 and W^2 appear;

each X is independently halo, for each ring system in which X appears;

each Y is independently selected from the group consisting of H, -$C(O)R^A$, -$C(O)N(R^A)_2$, glycosyl, -NO_2 and -$PO(OR^A)_2$, for each ring system in which Y appears, wherein each R^A is independently selected from the group consisting of H, -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_3-C_8 carbocyclyl and -C_1-C_{20} alkyl$N(R)_2$, wherein said -C_1-C_{20} alkyl, -C_1-C_8 heteroalkyl, -C_3-C_8 carbocyclyl and -C_1-C_{20} alkyl$N(R)_2$ are optionally substituted with 1 to 3 subsitutents independently selected from R;

L^1 and L^2 are each independently a direct bond; and

T is -$C(A^1)X^1$-T^2-$X^1C(B^1)$-, where T^2 is:



wherein each X^1 is a bond, wherein A^1 and B^1 are each independently =O, wherein R^1, R^2, R^3, and R^4 are each independently H wherein g and j are each independently 0 or 1 and m is 1, and wherein D is -C_3-C_8 carbocyclo, where said -C_3-C_8 carbocyclo is optionally substituted with -NH_2, -N(R)C(O)H or -N(R)C(O)OH.

9. The compound of any of claims 2 and 4, or a pharmaceutically acceptable salt, wherein:

L^A is selected from the group consisting of -halo, $-N(R)_2$, $-CON(R)_2$, -S-aryl optionally substituted with $-NO_2$ or $-CON(R)_2$, -S-heteroaryl optionally substituted with $-NO_2$, alkyl-SO_2-heteroaryl, arylSO_2-heteroaryl-, and



,

L^B is L^{B1}-L^{B2}-L^{B3} wherein L^{B1} is absent or is one or more components selected from the group consisting of -C(O)- , -C(S)- , -C(O)NR-, $-C(O)C_1$-C_6alkyl-, $-C(O)NRC_1$-C_6alkyl-, $-C_1$-C_6alkyl$(OCH_2CH_2)_{1-6}$-, $-C(O)C_1$-C_6alkylNRC(O)-, $-C(O)C_1$-C_6alkyl$(OCH_2CH_2)_{1-6}$-, $-C_1$-C_6alkyl$(OCH_2CH_2)_{1-6}$-C(O)-, $-C_1$-C_6alkyl-S-S-C_1-C_6alkylNRC(O)CH_2-, $-C_1$-C_6alkyl$(OCH_2CH_2)_{1-6}$NRC(O)CH_2-, $-C(O)C_1$-C_6alkyl-NRC(O)C_{1-6}alkyl-, $-C(O)$-C_1-C_6alkyl$(OCH_2CH_2)_{1-6}$NRC(O)-, $-C(O)C_1$-C_6alkyl-phenyl(NR-C(O)C_1-C_6alkyl)$_{1-4}$-, $-C(O)C_1$-C_6alkyl$(OCH_2CH_2)_{1-5}$-NRC(O)C_1-C_6alkyl-, $-C_1$-C_6alkyl-, -S- , -C(O)-CH(NR-C(O)C_1-C_6alkyl)-C_1-C_6alkyl- and $(-CH_2-CH_2-O-)_{1-20}$, wherein L^{B2} is AA_{0-12}, wherein AA is a natural amino acid, or a non-natural amino acid,

and L^{B3} is  ,  or absent; and

L^C is absent.

10. The compound of any of claims 3 and 5, or a pharmaceutically acceptable salt wherein:

L^A is selected from: a bond to AB, -NR-(bond to AB), alkyl-SO_2-heteroaryl, arylSO_2-heteroaryl-,

 ,  and  ;

L^B is L^{B1}-L^{B2}-L^{B3} wherein L^{B1} is absent or is one or more components selected from the group consisting of -C(O)- , -C(S)- , -C(O)NR-, -C(O)C_1-C_6alkyl-, -C(O)NRC_1-C_6alkyl-, -C_1-C_6alkyl(OCH_2CH_2)$_{1-6}$-, -C(O)C_1-C_6alkylNRC(O)-, -C(O)C_1-C_6alkyl(OCH_2CH_2)$_{1-6}$-, -C_1-C_6alkyl(OCH_2CH_2)$_{1-6}$-C(O)-, -C_1-C_6alkyl-S-S-C_1-C_6alkylNRC(O)CH_2-, -C_1-C_6alkyl(OCH_2CH_2)$_{1-6}$NRC(O)CH_2-, -C(O)C_1-C_6alkyl-NRC(O)C_1-C_6alkyl-, -C(O)-C_1-C_6alkyl(OCH_2CH_2)$_{1-6}$NRC(O)-, -C(O)C_1-C_6alkyl-phenyl(NR-C(O)C_1-C_6alkyl)$_{1-4}$-, -C(O)C_1-C_6alkyl(OCH_2CH_2)$_{1-6}$-NRC(O)C_1-C_6alkyl-, -C_1-C_6alkyl-, -S- , -C(O)-CH(NR-C(O)C_1-C_6alkyl)-C_1-C_6alkyl- and (-CH_2-CH_2-O-)$_{1-20}$, wherein L^{B2} is AA_{0-12}, wherein AA is a natural amino acid, or a non-natural amino acid,

and L^{B3} is  or absent; and

L^C is absent.

11. The compound of claim 1, wherein each V^1 is O, for each ring system in which V^1 appears; and each Y is independently selected from the group consisting of H, -C(O)N(R^A)$_2$, -C(S)N(R^A)$_2$, -PO(OR^A)$_2$ or glycosyl for each ring system in which Y appears, wherein each R^A is independently selected from the group consisting of H, -C_1-C_{20} alkyl,and -C_1-C_{20} alkylN(R)$_2$, and wherein said -C_1-C_{20} alkyl, and -C_1-C_{20} alkylN(R)$_2$ are optionally substituted with 1 to 3 subsitutents independently selected from R.

12. The compound according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, where one or more W is C_1-C_3 alkyl.

13. The compound according to any one of claims 1-5 , or a pharmaceutically acceptable salt thereof,where one or more X is chloro.

14. The compound according to any one of claims 1-5 , or a pharmaceutically acceptable salt thereof, where one Y is H or –C(O)C_1-C_{16}alkyl.

15. The compound according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, where one or more Z is H.

16. A compound, or a pharmaceutically acceptable salt thereof, selected from:

























































and

17. A compound, or a pharmaceutically acceptable salt thereof, selected from:













, and

18. A compound, or a pharmaceutically acceptable salt thereof, selected from:























































and



19. A compound, or a pharmaceutically acceptable salt thereof, selected from:











and



20. A linker-payload or an antibody-drug-conjugate, or a pharmaceutically acceptable salt thereof, comprising a radical of a compound of claim 16 or claim 17.

21. A compound, or a pharmaceutically acceptable salt thereof, selected from:





































and



22. A compound, or a pharmaceutically acceptable salt thereof, selected from:











PC72042



























and



23. A compound, or a pharmaceutically acceptable salt thereof, selected from:











and



24. A compound, or a pharmaceutically acceptable salt thereof, selected from:











and



25. A compound, or a pharmaceutically acceptable salt thereof, selected from:











, and



where X is an IL13 antibody or Y is VEGF antibody.

26. A compound, or a pharmaceutically acceptable salt thereof, selected from:



RC72042









and



where X is an IL13 antibody or Y is VEGF antibody.

27. A compound, or a pharmaceutically acceptable salt thereof, selected from:

RC72042




Cl
Cl
HO
OH
(X or Y)
NH
NH2


Cl
Cl
HO
OH
(X or Y)
NH
NH2



where X is an IL13 antibody or Y is VEGF antibody.

28. A compound, or a pharmaceutically acceptable salt thereof, selected from:


(X or Y)
(X or Y)
(X or Y)


Cl
Cl
HO
OH
(X or Y)
NH
NH2


Cl
Cl
HO
OH
(X or Y)
NH
NH2



where X is an IL13 antibody or Y is VEGF antibody.

29. A pharmaceutical composition comprising a compound of any one of claims 1 to 28 or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipient.

30. The pharmaceutical composition of claim 29, for the treatment of cancer.

31. The pharmaceutical composition of Claim 30, wherein said cancer is bladder cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, kidney cancer, lung cancer, esophageal cancer, ovarian cancer, prostate cancer, pancreatic cancer, skin cancer, stomach (gastric) cancer, testicular cancer, leukemias and lymphomas.